ALPHA TAU MEDICAL LTD (DRTS) Forecast, Price Target & Analyst Ratings

NASDAQ:DRTS • IL0011839383

Current stock price

7.88 USD
+0.05 (+0.64%)
At close:
8.14 USD
+0.26 (+3.3%)
Pre-Market:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ALPHA TAU MEDICAL LTD (DRTS).

Forecast Snapshot

Consensus Price Target

Price Target
$9.69
+ 22.97% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
N/A
Period
Q1 / 2026
EPS Estimate
-$0.13
Revenue Estimate
96.9K
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
84.00%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$9.69
Upside
+ 22.97%
From current price of $7.88 to mean target of $9.69, Based on 10 analyst forecasts
Low
$5.05
Median
$10.71
High
$12.60

Price Target Revisions

1 Month
15.15%
3 Months
15.15%

Price Target Summary

10 Wall Street analysts provided a forecast for the next 12 months for DRTS. The average price target is 9.69 USD. This implies a price increase of 22.97% is expected in the next year compared to the current price of 7.88.
The average price target has been revised upward by 15.15% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

DRTS Current Analyst RatingDRTS Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0 0 0 0 0

Analyst Ratings History

DRTS Historical Analyst RatingsDRTS Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8

Analyst Ratings Consensus

ChartMill Buy Consensus
84.00%
DRTS was analyzed by 10 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about DRTS.
In the previous month the buy percentage consensus was at a similar level.
DRTS was analyzed by 10 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-03-11CitigroupMaintains Buy -> Buy
2026-03-10HC Wainwright & Co.Reiterate Buy -> Buy
2026-03-04Piper SandlerDowngrade Overweight -> Neutral
2026-02-24HC Wainwright & Co.Maintains Buy -> Buy
2025-12-10CitigroupMaintains Buy -> Buy
2025-11-24HC Wainwright & Co.Reiterate Buy -> Buy
2025-10-22HC Wainwright & Co.Reiterate Buy -> Buy
2025-09-03HC Wainwright & Co.Reiterate Buy -> Buy
2025-04-29HC Wainwright & Co.Reiterate Buy -> Buy
2025-03-17HC Wainwright & Co.Reiterate Buy -> Buy
2024-11-22HC Wainwright & Co.Reiterate Buy -> Buy
2024-10-23HC Wainwright & Co.Reiterate Buy -> Buy
2024-10-11HC Wainwright & Co.Reiterate Buy -> Buy
2024-08-20HC Wainwright & Co.Reiterate Buy -> Buy
2024-08-15Piper SandlerReiterate Overweight -> Overweight
2024-06-26HC Wainwright & Co.Reiterate Buy -> Buy
2024-05-22HC Wainwright & Co.Reiterate Buy -> Buy
2024-05-16HC Wainwright & Co.Reiterate Buy -> Buy
2024-03-12HC Wainwright & Co.Reiterate Buy -> Buy
2024-03-08Piper SandlerReiterate Overweight -> Overweight
2023-12-15CitigroupInitiate Buy
2023-11-20HC Wainwright & Co.Reiterate Buy -> Buy
2023-11-17Piper SandlerMaintains Overweight -> Overweight
2023-09-20HC Wainwright & Co.Reiterate Buy -> Buy
2023-08-29Cantor FitzgeraldReiterate Overweight -> Overweight

Next Earnings Forecast Details

Next Earnings Details

Release Date
N/A
Period
Q1 / 2026
EPS Estimate
-$0.13
Revenue Estimate
96.9K
Revenue Q2Q
N/A
EPS Q2Q
-8.80%
Number of Analysts
6

Next Earnings Revisions

Revenue (1 Month)
50.01%
Revenue (3 Months)
119.25%
EPS (1 Month)
-9.71%
EPS (3 Months)
-6.67%

Next Earnings Summary

The next earnings revenue estimate has been revised upward by 119.25% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2030

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
DRTS revenue by date.DRTS revenue by date.
N/AN/A
965.57%		N/A
614.58%		N/A
137.82%		N/A
52.50%
EBITDA
YoY % growth
DRTS ebitda by date.DRTS ebitda by date.
-7.94M-9.15M
-15.24%		-13.01M
-42.19%		-31.16M
-139.51%		-34.606M
-11.06%		-34.94M
-0.97%		-41.056M
-17.50%		N/A
-27.69%		N/A
15.56%		N/A
179.18%		N/AN/A
EBIT
YoY % growth
DRTS ebit by date.DRTS ebit by date.
-8.01M-9.24M
-15.36%		-13.79M
-49.24%		-32.14M
-133.07%		-35.68M
-11.01%		-36.042M
-1.01%		-42.288M
-17.33%		N/A
-15.71%		N/A
2.98%		N/A
98.26%		N/A
6,100.00%		N/A
106.02%
Operating Margin
DRTS operating margin by date.DRTS operating margin by date.
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
EPS
YoY % growth
DRTS eps by date.DRTS eps by date.
N/AN/AN/A-0.66
-148.87%		-0.42
36.36%		-0.45
-7.14%		-0.47
-4.44%		N/A
-13.00%		N/A
11.94%		N/A
116.03%		N/A
689.12%		N/A
100.00%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27 Q1 / 28 Q2 / 28 Q3 / 28 Q4 / 28
EPS
Q2Q % growth		-0.13
-8.80%		-0.13
-0.96%		-0.13
6.25%		-0.13
-64.05%		-0.12
6.25%		-0.11
14.51%		-0.11
14.51%		-0.12
6.74%		-0.10
16.67%		-0.08
27.27%		-0.08
27.27%		-0.06
50.00%
Revenue
Q2Q % growth		96.9K193.8K239.7K433.5K1.153M
1,089.89%		1.928M
894.84%		2.122M
785.27%		2.509M
478.78%		5.069M
339.64%		8.211M
325.88%		9.068M
327.33%		13.903M
454.13%
EBITDA
Q2Q % growth		-12.977M
-31.71%		-13.102M
-43.74%		-13.148M
-22.26%		-13.195M
-16.05%		N/AN/AN/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth		-12.463M
-33.90%		-12.552M
-30.10%		-12.496M
-16.46%		-12.781M
-1.42%		-12.672M
-1.68%		-12.295M
2.05%		-12.451M
0.36%		-13.26M
-3.75%		N/AN/AN/AN/A

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

DRTS Yearly Revenue VS EstimatesDRTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
DRTS Yearly EPS VS EstimatesDRTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 1

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
29.26%
EPS Next 5 Year
35.20%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
41.78%
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

ALPHA TAU MEDICAL LTD / DRTS Forecast FAQ

What is the price target for DRTS stock?

10 analysts have analysed DRTS and the average price target is 9.69 USD. This implies a price increase of 22.97% is expected in the next year compared to the current price of 7.88.

What are the consensus estimates for DRTS stock next earnings?

The consensus EPS estimate for the next earnings of ALPHA TAU MEDICAL LTD (DRTS) is -0.13 USD and the consensus revenue estimate is 96.90K USD.

How many analysts have analysed ALPHA TAU MEDICAL LTD (DRTS)?

The number of analysts covering ALPHA TAU MEDICAL LTD (DRTS) is 10.